How golden is the gold standard of neuropathology in dementia?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Current Alzheimer's disease (AD) criteria state that a definite diagnosis can only be made by postmortem examination. The neuropathological confirmation is often referred to as the “gold standard.” In this article, we review what constitutes a gold standard and how the neuropathological examination of AD lives up to that standard. We conclude that there is no evidence for this notion because results between different laboratories differ to an important extent, especially when the clinical picture is in doubt, for example, when the dementia is mild. As an alternative, we propose to abandon thinking in standards and value neuropathology as any other biomarker, and to strive to use and integrate multiple sources of information to make the diagnosis of AD in all its complexity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 2×
“If neuropathology is not the standard, are there alternatives to which a clinical diagnosis might be compared? There is some enthusiasm for biomarkers [9,10], although there is reason to be cautious about the results, especially at this early stage, illustrated by the results of a pan-European effort [11,12].”
Background(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
White, L. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1178 · Cited by 193
Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium
Alafuzoff, I., Thal, D. R., Arzberger, T., Bogdanovic, N., Al-Sarraj, S., Bodi, I., Boluda, S., Bugiani, O., Duyckaerts, C., Gelpi, E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0485-4 · Cited by 193
MIRRA, S. S., GEARING, M., MCKEEL, D. W., CRAIN, B. J., HUGHES, J. P., BELLE, G. V., & HEYMAN, A. (1994) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199405000-00012 · Cited by 156
Cited by
Arevalo-Rodriguez, I., Smailagic, N., Roqué i Figuls, M., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., Pedraza, O. L., Bonfill Cosp, X., & Cullum, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010783.pub2 · Cited by 831
Creavin, S. T., Wisniewski, S., Noel-Storr, A. H., Trevelyan, C. M., Hampton, T., Rayment, D., Thom, V. M., Nash, K. J. E., Elhamoui, H., Milligan, R., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011145.pub2 · Cited by 820
Arevalo-Rodriguez, I., Smailagic, N., Roqué-Figuls, M., Ciapponi, A., Sanchez-Perez, E., Giannakou, A., Pedraza, O. L., Bonfill Cosp, X., & Cullum, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010783.pub3 · Cited by 461
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Westman, E., Muehlboeck, J.-S., & Simmons, A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.04.056 · Cited by 302
Metadata
- Authors
- Scheltens, P., & Rockwood, K.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 7
- Issue
- 4
- Pages
- 486-489
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2047732935
- Cited by
- 82
- References
- 6
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How golden is the gold standard of neuropathology in dementia? https://app.cochat.ai/papers/10.1016/j.jalz.2011.04.011
- The paper
- Scheltens, P., & Rockwood, K. (2011). How golden is the gold standard of neuropathology in dementia? Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2011.04.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.